Quick Summary
Ancillary supplies have always been part of clinical trial planning, but they haven’t always received the level of attention they deserve. Increasingly, sponsors, CROs, and clinical supply teams are recognizing how much non‑drug materials, everything from equipment to kitted supplies, can influence timelines, logistics, and overall study execution. The industry is pushing for more clarity in five areas: ownership, definition, complexity and appreciation, timing, and logistics. The GCSG’s recent focus reflects this shift, and the way the industry manages non‑drug supply chain issues is expected to take on an even larger role this year.
____________________________________________
Ancillary Supplies Reshape Clinical Trial Supply Planning
Clinical trial ancillary supplies have always been part of the clinical supply picture, but lately they’ve been getting more deliberate attention. Over the last year, I’ve seen more sponsors, CROs, and supply teams taking a closer look at how ancillary equipment, supplies, and kitting can affect study timelines just as much as drug availability.
What was once considered a background responsibility is becoming a more visible and actively managed component of the clinical supply strategy. That shift showed up clearly at this year’s Global Clinical Supplies Group (GCSG) North American conference in San Diego, where planning for clinical trial ancillary supplies, equipment, and kitting came up far more often than in past years.
A New Focus
I see that attention for ancillary supplies in clinical trials is focused on five areas:
1. Owners
Ancillary supplies, equipment, and kitting tend to fall into the clinical trial black hole. Depending on who you talk to, ownership might sit with:
- Clinical supply
- Clinical operations
- The CRO
- Whoever happens to be closest to the problem when the need pops up
It’s often a last-minute scramble to figure out who actually owns it. At GCSG, one person told me ownership “depends on the study and the team.” That captures the ambiguity that many groups are trying to bring clarity to.
2. Definition
Are ancillaries part of the clinical trial supply chain? It sounds like a simple question, but there’s no clear-cut answer. Different people define the category differently, and those definitions shape who owns it, how it’s planned, and when it’s addressed.
3. Complexity and Appreciation
Teams are increasingly zeroing in on the complexities that exist with identifying, sourcing, storing, and globally distributing non-drug study supplies. After a workshop focused on ancillaries, a senior clinical supply leader at a global mid-size sponsor told me he believes ancillaries are the most complex element of the supply chain.
Teams often come to appreciate that complexity the moment a missing or delayed item puts pressure on a study visit. Having an infusion drug at the site without infusion supplies is just as disruptive as not having the drug at all. That kind of experience narrows the industry’s focus to this part of the supply chain.
4. Timing
To complement the point above, ancillary supplies, equipment, and kitting need to be part of every clinical trial supply plan. Teams have to track inventory and forecast resupply just as they do with a drug. When equipment is involved, maintenance and calibration schedules must also be monitored. Early, detailed planning is essential, and ongoing tracking and support are required for successful execution, especially on a global scale.
5. Logistics
Pivotal studies are increasingly multinational, which makes ancillary logistics more complex than ever. Check the news on any given day, and the challenges are obvious: trade wars, armed conflicts, shifting border controls, fuel price volatility, and sustainability pressures. There is no shortage of challenges involved in moving supplies across the globe. Drugs are highly regulated, and so are many kinds of medical supplies, peripherals, and equipment.
GCSG’s Growing Focus on Ancillary Supplies in Clinical Trials
With this evolving understanding, GCSG has given more attention to weaving ancillary supplies in clinical trials into the conference curriculum. This year’s North American meeting included more sessions on the topic than the previous year, and I saw non‑drug supply challenges surface in discussions about global logistics, supply management software, and regulatory compliance. A growing number of vendors are also demonstrating capabilities in this space, reflecting how quickly the field is maturing.
Looking ahead to 2026 and the GCSG European Knowledge Forum, it’s clear that non‑drug supply chain matters will continue to draw more of the spotlight. The real‑world challenges sponsors and CROs face in the global operating environment are pushing the industry toward deeper expertise across every element of clinical supply.
The Imperial Advantage
As ancillary supplies in clinical trials take on a larger role in planning, the operational demands are getting more complex.
We help sponsors and CROs with integrated planning, global logistics expertise, and the ability to manage every component within a single, coordinated system. That alignment reduces ambiguity, shortens response times, and strengthens study execution. As the industry sharpens its focus on ancillaries, we’re positioned to support teams with clarity and structure.
